LAUSR

The specific description, risk factors, and outcomes of aGVHD in pediatric haplo‐HSCT using TCR protocols without PT‐Cy have not been well described previously. We evaluated the incidence, risk factors, and outcomes of aGVHD in 350 consecutive pediatric patients receiving TCR haplo‐HSCT without PT‐Cy according to the Glucksberg and NIH aGVHD classifications between January 2015 and December 2017 at Peking University Institute of Hematology. The cumulative incidences of grade I, II, III, and IV aGVHD were 28%, 29.7%, 8.3%, and 5.1%, respectively. The type of aGVHD onset was classic in 243 patients (97.2%), and persistent/recurrent/late‐onset aGVHD was in seven patients (2.8%). None of the considered variables significantly influenced the incidence of grade III‐IV aGVHD. The 3‐year OS, DFS, cumulative incidence of NRM, and relapse in malignant disease between severe aGVHD (III‐IV) group and grade 0‐II aGVHD group were 61.5% vs 77.2% (P = .027), 58.6% vs 75.1% (P = .014), 19.8% vs 5.3% (P = .002), and 21.6% vs 19.6% (P = .59), respectively; in non‐malignant diseases, the 3‐year OS, DFS, and NRM were 81.8% vs 97.4% (P = .05), 81.8% vs 97.4% (P = .05), and 18.2% vs 2.6% (P = .05), respectively. Under the protocol of pediatric TCR haplo‐HSCT without PT‐Cy, the persistent/recurrent/late‐onset aGVHD was rare, and the incidence of severe aGVHD was acceptable and significantly contributed to NRM and lower survival in both malignant disease and non‐malignant diseases.